行情

DERM

DERM

Dermira
NASDAQ

实时行情|Nasdaq Last Sale

7.76
-0.33
-4.08%
交易中 13:02 11/14 EST
开盘
8.01
昨收
8.09
最高
8.09
最低
7.68
成交量
31.51万
成交额
--
52周最高
15.48
52周最低
5.25
市值
4.23亿
市盈率(TTM)
-1.6944
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

DERM 新闻

  • 美国消费者舒适度指数创下2008年以来最大三周降幅
  • 新浪美股.2小时前
  • 苹果罕见被评为“卖出” Maxim不看好iPhone销售
  • 新浪美股.2小时前
  • 美国预算赤字将达万亿 经济衰退或不可避免
  • 新浪财经-自媒体综合.2小时前
  • 开盘:关注联储官员讲话 美股周四小幅低开
  • 新浪美股.3小时前

更多

所属板块

生物技术和医学研究
-0.08%
制药与医学研究
-0.45%

热门股票

名称
价格
涨跌幅

DERM 简况

Dermira, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor that is approved and marketed for the treatment of numerous inflammatory diseases spanning multiple medical specialties, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease, in multiple countries, including the United States. Glycopyrronium tosylate is a small molecule anticholinergic product for topical application for the treatment of primary axillary hyperhidrosis. Olumacostat glasaretil is a small molecule that targets sebum production following topical application for the treatment of acne.
展开

Webull提供Dermira Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。